SAGE News and Press, Sage Therapeutics Inc. From 08/07/23

2023-08-07 12:05:00 ET Summary HSBC planning to shift its global HQ; Office markets saw "heightened uncertainty" in Q2 - JLL. Tyson Foods posts results miss; Campbell Soup to buy Sovos Brands in a $2.7B deal. Jefferies says "recession is almost inevitable". Listen be...

2023-08-07 10:15:28 ET Gainers: Poseida Therapeutics ( PSTX ) +33% . Tabula Rasa HealthCare ( TRHC ) +32% . Mallinckrodt plc ( MNK ) +17% . Assertio Holdings ( ASRT ) +18% . Palatin Technologies ( PTN ) +16% . Losers: Sag...

2023-08-07 10:04:18 ET Summary Sage Therapeutics, specializing in brain health, faces mixed financials with a decline in cash and an increase in expenses but anticipates revenue growth. Despite FDA approval for Zurzuvae (zuranolone) in PPD treatment, label warnings and controlled ...

2023-08-07 08:21:42 ET Sage Therapeutics ( SAGE ) -47% after Q2 earning release . Yellow Corporation ( YELL ) -43% files for bankruptcy after prolonged labor row . Apellis Pharmaceuticals ( APLS ) -15% . ADTRAN Holdings ( ADTN ) -14% aft...

2023-08-07 06:30:59 ET Sage Therapeutics press release ( NASDAQ: SAGE ): Q2 GAAP EPS of -$2.68 misses by $0.11 . Revenue of $2.47M (+64.7% Y/Y) misses by $0.44M . For further details see: Sage Therapeutics GAAP EPS of -$2.68 misses by $0.11, revenue of $2...

ZURZUVAE™ (zuranolone) approved as first-and-only oral treatment specifically indicated for adults with postpartum depression (PPD) and on-track for planned launch in the fourth quarter of 2023 shortly after DEA scheduling Sage brain health pipeline provides potential for significa...

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that it will host a live webcast on Monday, August 7, 2023 at 8:00 a.m. ET to provide a business update. Second quarter 2023 financial results will also ...

Postpartum depression (PPD) approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with sustained effect to Day 45 Mental health conditions are the leading cause of maternal mort...

2023-07-26 15:46:00 ET Shares of the brain-health specialist Sage Therapeutics (NASDAQ: SAGE) are having a tough trading session today. Specifically, the biotech's stock was down by approximately 13% on heavy volume as of 2:38 p.m. ET Wednesday afternoon. The spark? Yesterday, ...

2023-07-26 13:36:56 ET Sage Therapeutics ( NASDAQ: SAGE ) lost more than 14% Wednesday to reach the lowest level since November amid investor concerns over its depression therapy, zuranolone, as the FDA is set to decide on its marketing application by early August. In March,...